1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 2,300 | 2,800 | 14:41 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 20.10. | ABL Diagnostics: ABL Texcell Diagnostics Announces Termination of Vela Diagnostics Letter of Intent | 3 | Euronext | ||
| 20.10. | ABL Texcell Diagnostics Announces Termination of Vela Diagnostics Letter of Intent | 279 | Business Wire | The proposed acquisition in Singapore and the United States will not proceed
Regulatory News:
ABL Texcell Diagnostics (Euronext Paris: ABLD ISIN: FR001400AHX6) ("Company") an international life... ► Artikel lesen | |
| ABL DIAGNOSTICS Aktie jetzt für 0€ handeln | |||||
| 19.10. | ABL Diagnostics: ABL Texcell Diagnostics Strengthens the Foundations of a Stable Shareholder Base and Pursues Its Growth Strategy | 1 | Euronext | ||
| 19.10. | ABL Texcell Diagnostics SA: ABL Texcell Diagnostics Strengthens the Foundations of a Stable Shareholder Base and Pursues Its Growth Strategy | 343 | Business Wire | Its principal shareholder, ABL Luxembourg, intends to prioritize long-term investors in connection with any potential future disposals of significant blocks of shares
Regulatory News:
ABL Texcell... ► Artikel lesen | |
| 16.10. | ABL Diagnostics: ABL Texcell Diagnostics: Notice of Appeal by the Public Prosecutor Regarding the IntegraGen Transfer Judgment | 3 | Euronext | ||
| 16.10. | ABL Texcell Diagnostics SA: ABL Texcell Diagnostics: Notice of Appeal by the Public Prosecutor Regarding the IntegraGen Transfer Judgment | 357 | Business Wire | Regulatory News:
ABL Texcell Diagnostics (Euronext Paris: ABLD ISIN: FR001400AHX6)("Company") informs its shareholders and all stakeholders that it has been notified of the notice of appeal filed... ► Artikel lesen | |
| 12.10. | ABL Diagnostics: ABL Texcell Diagnostics Strengthens Its Presence at Genopole and Opens a New Chapter in Precision Oncology With the Acquisition of IntegraGen's Assets and Operations | 1 | Euronext | ||
| 12.10. | ABL Texcell Diagnostics Strengthens Its Presence at Genopole and Opens a New Chapter in Precision Oncology With the Acquisition of IntegraGen's Assets and Operations | 640 | Business Wire | A few months after integrating Texcell's activities, ABL Texcell Diagnostics strengthens its expertise in precision oncology, human genetics and rare diseases, while continuing to build a leading... ► Artikel lesen | |
| 08.10. | ABL Diagnostics: ABL Texcell Diagnostics Announces Availability of All Invest Securities Research Flash Note #8 | 2 | Euronext | ||
| 08.10. | ABL Texcell Diagnostics Announces Availability of All Invest Securities Research Flash Note #8 | 474 | Business Wire | Revised report includes the contribution from TEXCELL activities
Regulatory News:
ABL Texcell Diagnostics (Euronext Paris: ABLD ISIN: FR001400AHX6) (the "Company"), a company specializing in... ► Artikel lesen | |
| 01.10. | ABL Diagnostics: ABL Texcell Diagnostics Raises Its 2026 Revenue Guidance to €13.5 Million - €14.0 Million | 4 | Euronext | ||
| 01.10. | ABL Texcell Diagnostics Raises Its 2026 Revenue Guidance to €13.5 Million - €14.0 Million | 661 | Business Wire | Revised guidance includes the expected contribution from TEXCELL activities since their acquisition in the second half of 2026 Revised 2026 revenue guidance of €13.5 million to €14.0 million... ► Artikel lesen | |
| 30.09. | ABL Diagnostics: ABL Texcell Diagnostics: Availability of the 2026 Half-Year Financial Report | - | Euronext | ||
| 30.09. | ABL Texcell Diagnostics SA: ABL Texcell Diagnostics: Availability of the 2026 Half-Year Financial Report | 429 | Business Wire | Regulatory News:
ABL Texcell Diagnostics (Euronext Paris: ABLD ISIN: FR001400AHX6) (the "Company"), a company specializing in molecular diagnostic solutions, healthcare software and services supporting... ► Artikel lesen | |
| 21.09. | ABL Texcell Diagnostics SA: ABL Texcell Diagnostics Reaches a New Strategic Milestone With a Proposed Acquisition of Vela Diagnostics' Activities in Singapore and the United States | 921 | Business Wire | The Company signs a non-binding letter of intent to acquire 100% of Vela Operations Singapore and Vela Diagnostics USA, with the ambition to consolidate an integrated international platform covering... ► Artikel lesen | |
| 17.09. | ABL Diagnostics Becomes ABL Texcell Diagnostics | 625 | Business Wire | Shareholders confirm the continuation of the Company's listing on the regulated market of Euronext Paris as the most appropriate framework to support the Company's next phase of long-term development
Regulatory... ► Artikel lesen | |
| 17.09. | ABL Diagnostics Announces Its Participation in Investor Access @ Maison De La Chimie Paris 2026 | 337 | Business Wire | Regulatory News:
ABL Diagnostics (Euronext Paris Compartment B ISIN: FR001400AHX6 ABLD), an international company specializing in molecular diagnostic solutions, healthcare software and life sciences... ► Artikel lesen | |
| 15.09. | ABL Diagnostics to Participate in the European Main MidCap Event Paris 2026 on September 30 and October 1, 2026 | 467 | Business Wire | Regulatory News:
ABL Diagnostics (Euronext Paris Compartment B ISIN: FR001400AHX6 ABLD), an international company specializing in molecular diagnostic solutions, healthcare software and life sciences... ► Artikel lesen | |
| 14.09. | ABL Diagnostics SA: ABL Diagnostics Announces Availability of the Latest All Invest Securities Research Report | 622 | Business Wire | Regulatory News:
ABL Diagnostics (Euronext Paris: ABLD ISIN: FR001400AHX6) (the "Company"), a company specializing in molecular diagnostic solutions, healthcare software and clinical research services... ► Artikel lesen | |
| 11.09. | ABL Diagnostics (ABLD) Announces the Filing of a Takeover Bid for Integragen | 648 | Business Wire | Regulatory News:
ABL Diagnostics (Euronext Paris: ABLD ISIN: FR001400AHX6) (the "Company"), a company specialized in molecular diagnostics solutions, healthcare software and services supporting... ► Artikel lesen |
1 2 3 Weiter >>
54 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SIEMENS HEALTHINEERS | 43,190 | +0,70 % | EQS-CMS: Siemens Healthineers AG: Veröffentlichung einer Kapitalmarktinformation | EQS Zulassungsfolgepflichtmitteilung: Siemens Healthineers AG
/ Bekanntmachung nach Art. 5 Abs. 1 lit. b), Abs. 3 der Verordnung (EU) Nr. 596/2014, zuletzt geändert durch die Verordnung... ► Artikel lesen | |
| THERMO FISHER | 628,40 | -1,44 % | Argus raises Thermo Fisher stock price target on M&A strength | ||
| STRATEC | 23,000 | +1,10 % | BERENBERG stuft STRATEC BIOMEDICAL SYSTEMS AG auf 'Buy' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat die Einstufung für Stratec mit einem Kursziel von 37 Euro auf "Buy" belassen. Der Zulieferer für In-vitro-Diagnostik brauche wohl einen enormen... ► Artikel lesen | |
| UNIDOC HEALTH | 0,038 | +6,78 % | CSE Bulletin: Reinstatement - UniDoc Health Corp. (UDOC) | Le 7 octobre/October 2026
Effective immediately, UniDoc Health Corp. will be reinstated for trading.
The Company has rectified the default situation that gave rise to the suspension.
__________________________
En... ► Artikel lesen | |
| DIASORIN | 82,00 | +1,86 % | DiaSorin Reports Lower H1 Profit, Confirms FY26 Outlook | ROME (dpa-AFX) - DiaSorin S.p.A. (DIA.MI) on Friday, reported lower revenue and net profit for the first half of 2026, as higher operating expenses and weaker profitability offset growth recorded... ► Artikel lesen | |
| BRIGHTSPRING HEALTH SERVICES | 60,34 | +0,20 % | BrightSpring Health Services, Inc. - 10-Q, Quarterly Report | ||
| LIFESTANCE HEALTH GROUP | 13,635 | 0,00 % | LifeStance Health Group, Inc.: LifeStance Reports Strong Second Quarter 2026 Financial Results and Raises Full Year Outlook | SCOTTSDALE, Ariz., Aug. 06, 2026 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (Nasdaq: LFST), one of the nation's largest providers of outpatient mental healthcare, today announced financial... ► Artikel lesen | |
| FRESENIUS MEDICAL CARE | 40,920 | -1,33 % | JPMORGAN stuft FMC FRESENIUS MEDICAL CARE AG auf 'Underweight' | NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat FMC auf "Underweight" mit einem Kursziel von 32,30 Euro belassen. Entgegen seinen Erwartungen seien die Konsensschätzungen an die Quartalszahlen... ► Artikel lesen | |
| ALIGNMENT HEALTHCARE | 8,020 | -0,50 % | Alignment Healthcare Q3 2026 Earnings Call Transcript | ||
| FRESENIUS | 47,765 | +1,63 % | BERENBERG stuft Fresenius SE auf 'Buy' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat das Kursziel für Fresenius von 50 auf 54 Euro angehoben und die Einstufung auf "Buy" belassen. Der Markt bewerte den Medizinkonzern als vom... ► Artikel lesen | |
| HEARTFLOW | 60,55 | +0,03 % | Biotech Stocks At 52-Week Highs - Vaxcyte +31% On Phase 3 Results, InfuSystem, Illumina +7%, Charles River Laboratories +7%, HeartFlow +5% | SAN DIEGO (dpa-AFX) - The following biotech stocks reached a 52-week high on October 5, 2026, driven by key catalysts such as encouraging clinical research data.Vaxcyte Inc. (PCVX)Vaxcyte is... ► Artikel lesen | |
| BILLIONTOONE | 114,75 | -0,08 % | BillionToOne, Inc.: BillionToOne's Tissue-Free Northstar Response Demonstrates On-Par to Superior Cancer Treatment Monitoring vs. Tumor-Informed Assay, New Peer-Reviewed Study Finds | MENLO PARK, Calif., Oct. 07, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (Nasdaq: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are... ► Artikel lesen | |
| GENEDX | 70,98 | -0,06 % | GeneDx plans to add long-read genome sequencing to portfolio | ||
| CONCENTRA GROUP | 41,250 | 0,00 % | Biotech Stocks At 52-Week Highs - Retension Pharmaceuticals Rises With IPO, Biogen, Concentra Group, Hinge Health, HealthStream | WESTON (dpa-AFX) - The following biotech stocks reached a 52-week high on October 12, 2026, driven by catalysts such as achieving promising clinical data or a public offering.Biogen Inc. (BIIB)Biogen... ► Artikel lesen | |
| GERRESHEIMER | 33,040 | +3,57 % | Kurssprünge und neue Aufträge: Wie belastbar ist die Wende? dynaCERT, Gerresheimer, Steyr Motors | Ein Übernahmeangebot, internationale Vertriebsfortschritte und ein Konzernumbau bringen Bewegung in die folgenden drei Börsenwerte. Während Anleger auf neue Wachstumsimpulse und finanzielle Entlastung... ► Artikel lesen |
Das Unternehmen ABL DIAGNOSTICS SA kann der Branche Gesundheitswesen zugeordnet werden. Die relative Kursveränderung beträgt aktuell -6,31 % bei einem Aktienkurs von 1,930 Euro. Die Dividendendrendite beträgt aktuell +11,40 % (berechnet anhand der Ausschüttung von 0,22 Euro in den letzten 12 Monaten).
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ABL DIAGNOSTICS SA finden Sie auf Wallstreet Online.